Skip to main content

Meningitis Vaccine

Volume 400: debated on Tuesday 4 March 2003

The text on this page has been created from Hansard archive content, it may contain typographical errors.

To ask the Secretary of State for International Development what estimate the World Health Organisation has made of the number of doses of meningitis vaccine required and how many have been distributed in (a) Burkina Faso and (b) the Central African Republic. [100046]

a) Burkina Faso:

In the epidemic season 2001–02 there was a global shortage of tetravalent vaccine. In Burkina Faso, there were 13,000 cases, with 1,500 deaths. The target population for a mass vaccination campaign is an estimated 3.5 million people. The national authorities made no formal request for vaccines. The World Health Organisation (WHO) provided 25,000 doses of tetravalent (corresponding to a donation from Aventis) which were used to protect health workers.

So far in the epidemic season 2002–03, there has been 3,000 reported cases including 400 deaths. The national authorities have requested 1.4 million doses of the new GSK trivalent vaccine. WHO is in partnership with GSK to ensure widest use of this vaccine and are currently looking for funds from donors including the Gates Foundation. 500,000 doses have been sent so far with 1 million extra doses ready to be shipped.

b) Central African Republic (CAR):

The political situation in CAR is unstable and consequently it is difficult to collect reliable data. Medecins sans Frontieres (MSF) reported 60 cases in Bangassou and 20 cases in Mobaye between October and December 2002. CAR authorities requested 10,000 doses of tetravalent vaccine but due to the epidemiological figures and the absence of reliable lab data, no vaccination campaign has been implemented.